AbCellera Biologics Inc. Common Shares (ABCL) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on AbCellera Biologics Inc. Common Shares (ABCL) is Neutral.

The composite score behind that read is +0.15, weighing +0.37 of bullish evidence against -0.20 bearish.

AbCellera Biologics Inc. Common Shares last closed at $12.54, +4.33% on the session.

Against the IVW growth benchmark the position is +3.53% over the forecast window.

The read is built from 15 underlying insights — 3 bullish and 12 bearish.

Agreement across those insights is 80%.

7 graded predictions for ABCL so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks AbCellera Biologics Inc. Common Shares in the 28th percentile on return on equity, where 100 is best.

AbCellera Biologics Inc. Common Shares is classified under Health Care / Life Sciences Tools & Services, with a market capitalisation of $3.89B.

StockMap tracks AbCellera Biologics Inc. Common Shares as the 24th largest of the 41 companies it covers in the Life Sciences Tools & Services industry, part of the Health Care sector.

Across that group the current two-week reads are 37 Neutral, 2 Moderate Outperform and 2 Moderate Underperform.

On that composite AbCellera Biologics Inc. Common Shares ranks 4th of 41 in the group, against a group median of +0.06.